DPP4 and type 2 diabetes mellitus: Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become crucial in the treatment of type 2 diabetes mellitus.